HF
SCNI

HRT Financial’s Scinai Immunotherapeutics SCNI Stock Holding History

HRT Financial’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-356
Closed -$78K – 3970
2021
Q3 		$78K Buy
356
+33
+10% +$8.47K ﹤0.01% 2965
2021
Q2 		$92K Buy
323
+3
+0.9% +$934 ﹤0.01% 2606
2021
Q1 		$121K Buy
+320
New +$140K ﹤0.01% 2429

Other funds holding SCNI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

HRT Financial's SCNI Position: Q4 2021 in Review

HRT Financial sold out of Scinai Immunotherapeutics (SCNI) in Q4 2021, closing a stake of 356 shares — an estimated $78K sold.

HRT Financial first reported a position in SCNI in Q1 2021 and held it in 3 quarters. The position peaked at $121K in Q1 2021. 14 funds tracked by Wall St. Rank hold SCNI as of Q4 2021.

  • HRT Financial reported no remaining Scinai Immunotherapeutics position as of Q4 2021 after selling out during the quarter.
  • HRT Financial sold 356 Scinai Immunotherapeutics shares in Q4 2021, an estimated $78K.
  • HRT Financial first reported a position in Scinai Immunotherapeutics in Q1 2021 and held it in 3 quarters.
  • HRT Financial's Scinai Immunotherapeutics position peaked at $121K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2021.

Based on HRT Financial's 13F filing for Q4 2021, filed 14 Feb 2022.